Abstract:Objective: To review recent research advances on tau, a major player in Alzheimer's disease (AD) pathogenesis, a biomarker for AD onset, and potential target for AD therapy. Data sources: This review was based on a comprehensive search using online literature databases, including PubMed, Web of Science, and Google Scholar. Study selection: Literature search was based on the following keywords: Alzheimer's disease, tau protein, biomarker, cerebrospinal fluid (CSF), therapeutics, plasma, imaging, propagation, spreading, seeding, prion, conformational templating, and posttranslational modification. Relevant articles were carefully reviewed, with no exclusions applied to study design and publication type. Results: Amyloid plaques enriched with extracellular amyloid beta (Aβ) and intracellular neurofibrillary tangles comprised of hyperphosphorylated tau proteins are the two main pathological hallmarks of AD. Although the Aβ hypothesis has dominated AD research for many years, clinical Aβ-targeting strategies have consistently failed to effectively treat AD or prevent AD onset. The research focus in AD has recently shifted to the role of tau in AD. In addition to phosphorylation, tau is acetylated and proteolytically cleaved, which also contribute to its physiological and pathological functions. Emerging evidence characterizing pathological tau propagation and spreading provides new avenues for research into the molecular and cellular mechanisms underlying AD pathogenesis. Techniques to detect tau at minute levels in CSF and blood have been developed, and improved tracers have facilitated tau imaging in the brain. These advances have potential to accurately determine tau levels at early diagnostic stages in AD. Given that tau is a potential therapeutic target, anti-tau immunotherapy may potentially be a viable treatment strategy in AD intervention. Conclusion: Detecting changes in tau and targeting tau pathology represent a promising lead in the diagnosis and treatment of AD.

Tau Protein and Tauopathies: Exploring Tau Protein‐Protein and Microtubule Interactions, Cross‐Interactions and Therapeutic Strategies.

Atypical, non-standard functions of the microtubule associated Tau protein

Tau Protein Interaction Partners and Their Roles in Alzheimer’s Disease and Other Tauopathies

Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies

Post-Translational Modifications in Tau and Their Roles in Alzheimer's Pathology

Role of Tau Protein in Neurodegenerative Diseases and Development of Its Targeted Drugs: A Literature Review

Emerging Diagnostic and Therapeutic Strategies for Tauopathies

Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease

Cellular and pathological functions of tau

Tau in Health and Neurodegenerative Diseases

Tau: Enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies

Targeting Abnormal Tau Phosphorylation for Alzheimer's Therapeutics

Tauopathies: Mechanisms and Therapeutic Strategies

Amyloid-beta and tau protein beyond Alzheimer’s disease

Tau in Alzheimer's Disease: Mechanisms and Therapeutic Strategies.

Recent developments with tau-based drug discovery

Microtubule-associated protein tau as a therapeutic target in neurodegenerative disease

Small molecule therapeutics for tauopathy in Alzheimer’s disease: Walking on the path of most resistance

Disentangling tau: One protein, many therapeutic approaches

Tauopathies: new perspectives and challenges

Tau Proteolysis in the Pathogenesis of Tauopathies: Neurotoxic Fragments and Novel Biomarkers